

# Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.05.2024
6.0	06.07.2024	493796-00023	Date of first issue: 28.01.2016

# **SECTION 1: Identification of the substance/mixture and of the company/undertaking**

1.1 Product identifier Trade name		Cephapirin Formulation	
Trade name	•	Cephapini Formulation	
Other means of identification	:	Metricure (A007394) METRICURE BENZATHINE CEPHAPIRIN INTRA-UTERINE SUSPENSION (47091)	
1.2 Relevant identified uses of the	ne s	substance or mixture and uses advised against	
Use of the Sub- stance/Mixture	:	Veterinary product	
Recommended restrictions on use	:	Not applicable	
1.3 Details of the supplier of the	sa	fety data sheet	
Company	:	MSD	
		Kilsheelan Clonmel Tipperary, IE	
Telephone	:	353-51-601000	
E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com	
1.4 Emergency telephone number +1-908-423-6000	ər		
SECTION 2: Hazards identific	ati	on	
2.1 Classification of the substan	се	or mixture	
Classification (REGULATIO	N (I	EC) No 1272/2008)	
Respiratory sensitisation, Cate	•		
2.2 Label elements			
Labelling (REGULATION (EC	C) M	No 1272/2008)	
Hazard pictograms			
Signal word	:	Danger	
Hazard statements	:	H334 May cause allergy or asthma symptoms or breathing	
		1 / 15	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Cephapirin Formulation

Version 6.0	Revision Date: 06.07.2024	SDS Number: 493796-00023	Date of last issue: 16.05.2024 Date of first issue: 28.01.2016
		difficulties if inha	aled.
Preca	utionary statements	keep comfortab	If experiencing respiratory symptoms: Call a

Hazardous components which must be listed on the label: Cefapirin

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# **SECTION 3: Composition/information on ingredients**

## 3.2 Mixtures

## Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Cefapirin	21593-23-7	Resp. Sens. 1A;	>= 1 - < 10
	244-466-5	H334	

For explanation of abbreviations see section 16.

## **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection,

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Cephapirin Formulation

.0	Revision Date: 06.07.2024		OS Number: 3796-00023	Date of last issue: 16.05.2024 Date of first issue: 28.01.2016
				ommended personal protective equipment tial for exposure exists (see section 8).
lf inh	aled	:		give artificial respiration. fficult, give oxygen.
In ca	se of skin contact	:		r and soap as a precaution. ention if symptoms occur.
In ca	se of eye contact	:		water as a precaution. ention if irritation develops and persists.
lf swa	allowed	:	Get medical atte	D NOT induce vomiting. ention if symptoms occur. proughly with water.
.2 Most	important symptoms a	nd e	effects, both acu	te and delayed
Risks	3	:	May cause aller ties if inhaled.	gy or asthma symptoms or breathing difficul-
			other respiratory	sure may aggravate preexisting asthma and / disorders (e.g. emphysema, bronchitis, rea function syndrome).
.3 Indica	tion of any immediate	meo	other respiratory tive airways dys	y disorders (e.g. emphysema, bronchitis, rea function syndrome).
	<b>ition of any immediate</b> i ment	meo :	other respiratory tive airways dys dical attention ai	y disorders (e.g. emphysema, bronchitis, rea
Treat	-	:	other respiratory tive airways dys <b>dical attention a</b> Treat symptoma	y disorders (e.g. emphysema, bronchitis, rea function syndrome). nd special treatment needed
Treat	ment	:	other respiratory tive airways dys <b>dical attention a</b> Treat symptoma	y disorders (e.g. emphysema, bronchitis, rea function syndrome). nd special treatment needed
Treat	M 5: Firefighting meas	: sur	other respiratory tive airways dys <b>dical attention a</b> Treat symptoma	y disorders (e.g. emphysema, bronchitis, rea function syndrome). <b>nd special treatment needed</b> atically and supportively.
Treat SECTIOI .1 Exting Suita	ment N 5: Firefighting meas guishing media ble extinguishing media itable extinguishing	: sur	other respiratory tive airways dys dical attention au Treat symptoma es Water spray Alcohol-resistan Carbon dioxide	y disorders (e.g. emphysema, bronchitis, rea function syndrome). <b>nd special treatment needed</b> atically and supportively.
Treat SECTION .1 Exting Suita Unsu medi	ment N 5: Firefighting meas guishing media ble extinguishing media itable extinguishing	: sur :	other respiratory tive airways dys dical attention and Treat symptoma es Water spray Alcohol-resistant Carbon dioxide Dry chemical None known.	y disorders (e.g. emphysema, bronchitis, rea function syndrome). <b>Ind special treatment needed</b> atically and supportively.
Treat SECTION .1 Exting Suita Unsu medi .2 Speci	<b>N 5: Firefighting meas</b> <b>guishing media</b> ble extinguishing media itable extinguishing a <b>al hazards arising from</b> ific hazards during fire-	: sur :	other respiratory tive airways dys dical attention and Treat symptoma es Water spray Alcohol-resistan Carbon dioxide Dry chemical None known.	y disorders (e.g. emphysema, bronchitis, rea function syndrome). <b>Ind special treatment needed</b> atically and supportively.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Cephapirin Formulation**

Version 6.0	Revision Date: 06.07.2024		OS Number: 3796-00023	Date of last issue: 16.05.2024 Date of first issue: 28.01.2016
5.3 Advice	for firefighters			
	al protective equipment fighters	:		e, wear self-contained breathing apparatus. tective equipment.
Specif ods	ic extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

# **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so.

•	
	Prevent further leakage or spillage if safe to do so.
	Prevent spreading over a wide area (e.g. by containment or oil
	barriers).
	Retain and dispose of contaminated wash water.
	Local authorities should be advised if significant spillages
	cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

:

Methods for cleaning up	:	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent.
		Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

# **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures

See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Cephapirin Formulation**

Versi 6.0	ion	Revision Date: 06.07.2024		OS Number: 3796-00023	Date of last issue: 16.05.2024 Date of first issue: 28.01.2016
Local/Total ventilation Advice on safe handling Hygiene measures		::	Avoid breathing n Do not swallow. Avoid contact with Avoid prolonged Handle in accord practice, based o sessment Keep container tig Already sensitise to asthma, allergi should consult the tory irritants or se	h eyes. or repeated contact with skin. ance with good industrial hygiene and safety n the results of the workplace exposure as- ghtly closed. d individuals, and those susceptible es, chronic or recurrent respiratory disease, eir physician regarding working with respira-	
		:	If exposure to che flushing systems place. When usin nated clothing be The effective ope engineering contr appropriate dego	ration of a facility should include review of ols, proper personal protective equipment, wning and decontamination procedures, monitoring, medical surveillance and the	
7.2 C	onditio	ons for safe storage,	incl	uding any incom	patibilities
		ements for storage and containers	:		labelled containers. Keep tightly closed. nce with the particular national regulations.
,	Advice	on common storage	:	Do not store with Strong oxidizing a Gases	the following product types: agents
7.3 S	pecific	end use(s)			
	-			No doto ovoilable	

Specific use(s)	: No data available
-----------------	---------------------

# **SECTION 8: Exposure controls/personal protection**

# 8.1 Control parameters

# **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis		
Cefapirin	21593-23-7	TWA	0.4 mg/m3 (OEB 2)	Internal		
	Further information: RSEN					

# Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Glycerides, mixed	Workers	Inhalation	Long-term systemic	177,79 mg/m3



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

# Cephapirin Formulation

Ver 6.0	sion	Revision Date: 06.07.2024	SDS Num 493796-00			f last issue: 16.05.2024 f first issue: 28.01.2016	
	decano tanoyl	oyl and oc-				effects	
			Workers	Skin cont	act	Long-term systemic effects	25,21 mg/kg bw/day
			Consumers	Inhalation	)	Long-term systemic effects	43,84 mg/m3
			Consumers	Skin cont	act	Long-term systemic effects	12,61 mg/kg bw/day
			Consumers	Ingestion		Long-term systemic effects	12,61 mg/kg bw/day

## Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Glycerides, mixed decanoyl and	Oral (Secondary Poisoning)	0,03 mg/kg food
octanoyl		

#### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

## Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387
Filter type	:	Combined particulates and organic vapour type (A-P)

# **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Physical state	: suspension
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Cephapirin Formulation**

Vers 6.0	sion	Revision Date: 06.07.2024		S Number: 3796-00023	Date of last issue: 16.05.2024 Date of first issue: 28.01.2016
	Melting	point/freezing point	:	No data available	9
	Initial b range	oiling point and boiling	:	No data available	9
	Flamm	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available	2
		explosion limit / Lower bility limit	:	No data available	9
	Flash p	point	:	No data available	9
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	pН		:	No data available	9
	Viscosi Visc	ty cosity, kinematic	:	No data available	9
	Solubili Wat	ity(ies) er solubility	:	No data available	2
	Partitio octanol	n coefficient: n- /water	:	No data available	2
	Vapour	pressure	:	No data available	9
	Relative	e density	:	No data available	9
	Relativ	e vapour density	:	No data available	9
		e characteristics ticle size	:	No data available	9
9.2 (	<b>Other ir</b> Explosi	nformation	:	Not explosive	
	Oxidiziı	ng properties	:	The substance of	r mixture is not classified as oxidizing.
	Evapor	ation rate	:	No data available	9
	Molecu	lar weight	:	No data available	9

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Cephapirin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 16.05.2024
6.0	06.07.2024	493796-00023	Date of first issue: 28.01.2016

# **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

# **10.2 Chemical stability**

Stable under normal conditions.

# 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## **SECTION 11: Toxicological information**

## 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

#### Acute toxicity

Not classified based on available information.

## **Components:**

#### Cefapirin:

Acute oral toxicity	:	LD50 (Mouse): 26.000 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Mouse): > 7.600 mg/kg Application Route: Intraperitoneal
		LD50 (Rat): 7.800 mg/kg Application Route: Intraperitoneal

#### Skin corrosion/irritation

Not classified based on available information.

## Serious eye damage/eye irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Cephapirin Formulation**

sion	Revision Date: 06.07.2024	-	OS Number: 3796-00023	Date of last issue: 16.05.2024 Date of first issue: 28.01.2016
Respi	iratory or skin sensit	isatic	n	
Skin s	sensitisation			
Not cl	assified based on avai	ilable	information.	
Respi	iratory sensitisation			
May c	ause allergy or asthma	a sym	ptoms or breathing	ng difficulties if inhaled.
<u>Comp</u>	oonents:			
Cefap	pirin:			
Asses	ssment	:	Probability or ev humans	vidence of high respiratory sensitisation rate i
Germ	cell mutagenicity			
Not cl	assified based on avai	ilable	information.	
<u>Comp</u>	oonents:			
Cefap	birin:			
Genot	toxicity in vitro	:	Test Type: Bact Result: negative	erial reverse mutation assay (AMES)
	nogenicity assified based on avai	ilable	information.	
-	oductive toxicity assified based on avai	ilable	information.	
Comp	oonents:			
Cefap	birin:			
-	s on fertility	:	Species: Rat Application Rou	lity/early embryonic development te: Intraperitoneal injection .: > 500 mg/kg body weight cts on fertility
Effect ment	s on foetal develop-	:	Species: Rat Application Rou	oryo-foetal development ite: Intraperitoneal injection Toxicity: LOAEL: > 200 mg/kg body weight
	<b>- single exposure</b> assified based on avai	ilable	information.	
STOT	- repeated exposure	e		
Not cl	assified based on avai	ilable	information.	
Repe	ated dose toxicity			
Comr	onents:			

# Components:

# Cefapirin:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Cephapirin Formulation

Version 6.0	Revision Date: 06.07.2024	SDS Number: 493796-00023	Date of last issue: 16.05.2024 Date of first issue: 28.01.2016
	EL cation Route et Organs	: Rat : >= 200 mg/kg : Intraperitoneal : Blood : anemia	
Expo		: Dog : 20 mg/kg : Oral : 4 Months : Gastrointestina	tract
Expo	EL cation Route sure time et Organs	: Dog : 100 mg/kg : Intramuscular : 10 Months : Blood, Gastroin : anemia	testinal tract

# Aspiration toxicity

Not classified based on available information.

:

## 11.2 Information on other hazards

# Endocrine disrupting properties

## Product:

Assessment

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### Experience with human exposure

# Components:

## Cefapirin:

Ingestion

: Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, vaginitis, colitis, anorexia, Rash, anaphylaxis

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

No data available

# 12.2 Persistence and degradability

No data available

# 12.3 Bioaccumulative potential

No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Cephapirin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 16.05.2024
6.0	06.07.2024	493796-00023	Date of first issue: 28.01.2016

# 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

## **Product:**

Assessment

This substance/mixture contains no components considered 1 to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

# 12.6 Endocrine disrupting properties

Product:
----------

Assessment

The substance/mixture does not contain components consid-: ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# 12.7 Other adverse effects

No data available

# **SECTION 13: Disposal considerations**

13.1 Waste treatment methods	
Product	<ul> <li>Dispose of in accordance with local regulations.</li> <li>According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.</li> <li>Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.</li> <li>Do not dispose of waste into sewer.</li> </ul>
Contaminated packaging	<ul> <li>Empty containers should be taken to an approved waste han- dling site for recycling or disposal.</li> <li>If not otherwise specified: Dispose of as unused product.</li> </ul>


# **SECTION 14: Transport information**

14.1 UN number or ID number		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		

## ιH

ADN
-----

Not regulated as a dangerous good :





# Cephapirin Formulation

ADR       : Not regulated as a dangerous good         RID       : Not regulated as a dangerous good				
RID : Not regulated as a dangerous good				
IMDG : Not regulated as a dangerous good				
IATA : Not regulated as a dangerous good				
14.3 Transport hazard class(es)				
ADN : Not regulated as a dangerous good				
ADR : Not regulated as a dangerous good				
RID : Not regulated as a dangerous good				
IMDG : Not regulated as a dangerous good				
IATA : Not regulated as a dangerous good				
14.4 Packing group				
ADN : Not regulated as a dangerous good				
ADR : Not regulated as a dangerous good				
RID : Not regulated as a dangerous good				
IMDG : Not regulated as a dangerous good				
IATA (Cargo) : Not regulated as a dangerous good				
IATA (Passenger) : Not regulated as a dangerous good				
14.5 Environmental hazards				
Not regulated as a dangerous good				
14.6 Special precautions for user Not applicable				
14.7 Maritime transport in bulk according to IMO instruments				
Remarks : Not applicable for product as supplied.				

# **SECTION 15: Regulatory information**

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

: Conditions of restriction for the following entries should be considered: Number on list 75, 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Cephapirin Formulation

Version         Revision Date:         SDS Num           6.0         06.07.2024         493796-00	
---	--

If you intend to use this product as tattoo ink, please contact your vendor.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that de- plete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import	:	Not applicable
of dangerous chemicals Seveso III: Directive 2012/18/EU of the European Parlian major-accident hazards involving dangerous substances.		t and of the Council on the control of

Not applicable

# Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

## The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

# **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements H334	:	May cause allergy or asthma symptoms or breathing difficul- ties if inhaled.
Full text of other abbreviations		
Resp. Sens.	:	Respiratory sensitisation
ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by		

Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Miand Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard



# Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.05.2024
6.0	06.07.2024	493796-00023	Date of first issue: 28.01.2016

of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

## Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

### **Classification of the mixture:**

Resp. Sens. 1 H334

# Classification procedure:

Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Cephapirin Formulation**

Version	Revision Date:	SD
6.0	06.07.2024	493

)S Number: 3796-00023 Date of last issue: 16.05.2024 Date of first issue: 28.01.2016